

Department Summer Seminar Program 2016

* 1人15分前後：10分発表、5分討論を目安として下さい。

* パワーポイントスライドは英語でお願い致します。発表は日本語、英語、自由です。

* 第1日目 6月27日（月） June 27, Mon 13:00 ~ 17:55

I Immune Responses against Cancer/Sarcoma

【 13:00~14:30 Chairperson／T. Tsukahara 塚原 智英 】

1. Immunotherapy for sarcoma T. Tsukahara 塚原 智英
2. Targeting sarcoma stem cell E. Mizushima 水島 衣美
3. Establishment of an artificial CTL clone expressing the TCR reacting with sarcoma stem cell antigen. Y. Shibayama 芝山 雄二
4. History of Collaboration with Sapporo Medical University S. Toji 田路 真悟
(株式会社医学生物学研究所)
5. Identification of novel HLA-A*11:01-restricted CTL epitopes derived from PBF. D. Li 李 棟梁
(株式会社医学生物学研究所)
6. T cell immunomonitoring in patients immunized with HLA-A24 survivin-2B/PBF peptides. K. Watanabe 渡邊 一絵

Coffee Break 【 14:30~14:45 】

II New Technology and Next Generation Cancer Immunotherapy

【 14:45~16:00 Chairperson／O. Harada 原田 大 】

7. Recent update on Digital Pathology O. Harada 原田 大
8. Detection of colon cancer lymph node metastasis using Talaporfin. K. Furuya / L. Li 古屋 一成、李 黎明
(千歳科学技術大学)
9. Cell plasticity and heterogeneity in tumor tissue. S. Hashimoto 橋本 真一
(金沢大学)

10. Development of next generation gene-engineered immune cells
M. Nakatsugawa 中津川 宗秀

11. Analysis of the antitumour ability of the anti-DNAJB8 antibody
H. Tadano 只野 裕己

Coffee Break 【 16 : 00~16 : 10 】

- III MD/PhD Session**
【 16 : 10~17 : 10 Chairperson／M. Nakatsugawa 中津川 宗秀 】
12. ETAS, it protects us! A. Nakayama 中山 純子
13. The HLA-DR ligandome analysis of lymphoma cells Y. Hashino 橋野 結子
14. A new mode of CTL induction against unique antigens presented by tapasin-deficient cells.
T. Kikuchi 菊地 太郎
15. Identification of novel targets for cancer stem cell-targeting immunotherapy S. Uno 宇野 誓

- IV Clinical Immunopathology and Trials**
【 17 : 10~17 : 55 Chairperson／T. Kubo 久保 輝文 】
16. Epithelial Immunity: Analogy between Inflammation and Cancer T. Kubo 久保 輝文
17. B cell lymphoma, beyond the line of history. A. Murai 村井 愛子
18. Cancer vaccination therapy from a clinical point of view.
H. Shima 島 宏彰

Dinner Time 18 : 30 ~

* 第2日目 6月28日(火) June 28, Tue 9:00 ~ 12:00

V Tumor Antigens and Antigen Presentation

【 9:00~10:15 Chairperson／T. kanaseki 金関 貴幸 】

- | | |
|---|-------------------|
| 19. Catch 'neoantigens' if you can | T. Kanaseki 金関 貴幸 |
| 20. Mapping HLA class I ligandome by mass spectrometry | S. Tokita 時田 芹奈 |
| 21. A long non-coding RNA PVT1 as a novel source of cancer antigens | Y. Kikuchi 菊池 泰弘 |
| 22. The ASB4 natural peptide for CTL immunotherapy on cancer stem cells | S. Miyamoto 宮本 昇 |
| 23. Biological roles of the ASB4 gene | A. Hongo 本郷 歩 |

Coffee Break 【 10:15~10:30 】

VI Basic Research on Immunotherapy targeting Cancer Stem Cells

【 10:30~11:45 Chairperson／Y. Hirohashi 廣橋 良彦 】

- | | |
|---|--------------------|
| 24. The destination of cancer immunotherapy | Y. Hirohashi 廣橋 良彦 |
| 25. Expression & function associates with stem cell state in primary human colorectal cancer. | R. Ye 叶 烂 |
| 26. LYPD3 Expression Stem Cell State in Primary Human Colorectal Cancer | L. Wang 王 利明 |
| 27. Isolation and characterization of cancer stem-like cells from primary human endometrioid adenocarcinoma | Y. Tabuchi 田渕 雄大 |
| 28. Cancer testis antigen BORIS is expressed in lung cancer stem-like cells and can be a target of immunotherapy. | R. Horibe 堀部 亮多 |

VII Closing remarks

【 11:45~12:00 】

- | | |
|--|------------------|
| 29. Deep learning toward the top of cancer immunopathology | T. Torigoe 鳥越 俊彦 |
|--|------------------|